Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
Adamas Pharmaceuticals, Inc. (ADMS)
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adamaspharma.com/investors
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended release capsules, for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI was approved by the U.S. Food and Drug Administration (FDA) in August 2017, when it was granted seven years of orphan drug exclusivity, and has been available for physician and patient use since October 2017. Today’s launch marks the deployment of Adamas’ dedicated team of 59 neurology field sales professionals, who are focused on educating the Parkinson’s disease community about the benefit/safety profile of GOCOVRI. “The full commercial launch of GOCOVRI represents an important milestone for Adamas and will significantly expand awareness of GOCOVRI for both physicians and patients,” said Gregory T. Went, Ph.
Show less
Read more
Impact Snapshot
Event Time:
ADMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADMS alerts
High impacting Adamas Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics